Oct 10 (Reuters) - Surrozen Inc SRZN.O :
* SURROZEN PRESENTS DATA ON TWO LEAD THERAPEUTIC CANDIDATES
AT
UNITED EUROPEAN GASTROENTEROLOGY (UEG) WEEK
* SURROZEN - SZN-043 PRECLINICAL DATA SHOWS RAPID, TRANSIENT
INCREASES IN HEPATOCYTE PROLIFERATION & WAS WELL TOLERATED IN
NON-CLINICAL TOXICOLOGY STUDIES
* SURROZEN INC - SZN-1326 PRECLINICAL DATA SHOWS IMPROVED
INTESTINAL EPITHELIAL HEALING, RESTORED EPITHELIAL BARRIER
* SURROZEN INC - SZN-1326 PRECLINICAL DATA SHOWS REDUCED
COLITIS-ASSOCIATED COLLAGEN DEPOSITION AND WAS WELL TOLERATED IN
NON-CLINICAL TOXICOLOGY STUDIES
Source text for Eikon: ID:nGNX2bDrZ3
Further company coverage: SRZN.O
((Reuters.Briefs@thomsonreuters.com;))